Maternal and perinatal clinical outcomes in the EMmY study
| Outcomes | Intervention (myo-inositol) N=99, n (%) | Control (placebo) N=99, n (%) |
| Maternal | ||
| GDM (IADPSG) by 28 weeks | 14 (14.1) | 13 (13.1) |
| GDM (NICE) by 28 weeks | 14 (14.1) | 9 (9.1) |
| GDM (all definitions) by delivery | 24 (24.2) | 20 (20.2) |
| Pre-eclampsia | 3 (3) | 9 (9.1) |
| Hyperemesis | 3 (3) | 3 (3) |
| Third/fourth-degree tear | 2 (2) | 1 (1) |
| Postpartum haemorrhage | 17 (17.2) | 15 (15.2) |
| GA at delivery (weeks; mean SD) (88;89)* | 38.9 (3.2) | 38.8 (2.8) |
| Preterm delivery (<37 weeks) | 6 (6) | 10 (10.2) |
| Spontaneous vaginal delivery | 44 (44) | 45 (45.9) |
| Perinatal | ||
| Birth weight (g; mean SD) (87;88)* | 3260 (533.3) | 3251 (598) |
| Apgar score at 10 min (69;70)* | 10 (0.5) | 10 (0.8) |
| Respiratory distress syndrome | 1 (1) | 1 (1) |
| Large for GA | 6 (6.1) | 11 (11.2) |
| Small for GA | 18 (18.4) | 22 (22.4) |
| Admission to neonatal unit | 5 (5.1) | 3 (3) |
*Number of women in the intervention and control group, respectively.
GA, gestational age; GDM, gestational diabetes mellitus; IADPSG, International Association of Diabetes and Pregnancy Study Groups; NICE, National Institute for Health and Care Excellence.